BeiGene’s Immunotherapy Drug Shines in Phase ESCC Trial
On January 27th, BeiGene announced that a Phase 3 trial that evaluated its anti-PD1 antibody, tislelizumab met its primary endpoint of overall survival (OS) as compared to chemotherapy in patients …
Read More